FDA Issues Dietary Supplement Warning
For LipoKinetix®

This news report appeared in the IFT Weekly Newsletter,
published by the Institute of Food Technologists at http://www.ift.org/extra/newsletter/index.html

NOVEMBER 21, 2001

The Food and Drug Administration (FDA) is warning consumers to immediately stop use of the product LipoKinetix®, marketed as a dietary supplement by Syntrax Innovations, Inc. FDA has received multiple reports of persons who developed liver injury or liver failure while using LipoKinetix. LipoKinetix is currently being marketed for weight loss. It contains the ingredient norephedrine (also known as phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate.

According to the FDA, the injuries reported occurred in persons between 20 and 32 years of age. No apparent cause of liver injury was identified in these reports other than use of LipoKinetix. Liver injury developed between 2 weeks and 3 months of LipoKinetix use. Healthcare professionals and distributors have also been warned of LipoKinetix through letters from the FDA.